Skip to main content
. 2024 May 16;5(7):100685. doi: 10.1016/j.jtocrr.2024.100685

Table 2.

DLT in Assessable Patients

Parameter, (n%) Avelumab + Lorlatinib (n = 28) Avelumab + Crizotinib (n = 12)
DLT 2 (7) 5 (42)
 ALT increased 2 (7) 2 (17)
 AST increased 0 2 (17)
 ECG QT prolonged 0 1 (8)
 Febrile neutropenia 0 1 (8)
 Immune-mediated hepatitis 0 1 (8)
 Rash 0 1 (8)

Note: Patients with more than one DLT are counted only once.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLT, dose-limiting toxicity; ECG, electrocardiogram.